Nonetheless, recent advances in molecular characterization and diagnostic tools in cancer are gradually leading to the development of combined treatment strategies, associating PI3K/Akt/mTOR inhibitors with therapies targeting compensatory signaling pathways. This evidence concerns the gene AKT1 and cancer.